Erenumab, which is being co-developed by Novartis and Amgen, targets and blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, which is thought to have a key role in mediating
Having been granted fast track status recently, ezutromid has now been awarded rare pediatric disease designation. Ezutromid is a utrophin modulator with a potential disease modifying treatment for
The new collaboration will explore the potential benefits of combining BMS’ anti-PD-1 antibody with Nektar’s CD122-biased agonist, NKTR-214, in five tumor types. The phase 1/2 clinical trials will
The company reported positive topline results from a pre-planned interim analysis of ZUMA-1 for its product candidate, KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). The
The US drugmaker said its analysis determined that splitting Pfizer Innovative Health and Pfizer Essential Health would not improve cash flow or better position the businesses competitively. The
The company has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) based on the data from the phase 3 Sirround clinical development
The approvals for the new indications, tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF), were based on clinical
The watchdog published draft guidance backing the drug's use in perinatal- and infantile-onset hypophosphatasia (HPP), a rare, and sometimes fatal, metabolic bone disease. The guidance, however, do not
SD-809 is an investigational, oral, small-molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being developed to treat chorea associated with Huntington disease. The positive data
The drug, dubbed Invokamet XR, is a combination of canagliflozin, a sodium glucose cotransporter 2 inhibitor found in Janssen’s Invokana, and an XR formulation of metformin, a commonly
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.